Journalists from Chinese medicines and health products import and export Chamber of Commerce was informed that, in October this year, China's pharmaceutical import and export ring than the "rare" double down. According to the Association General Director Xu Ming forecast, due to exchange rate and raw material prices, nearly thirty family medicine import and export Enterprise challenge will continue at least in the first half of next year.
Data show that in October 2010, China's pharmaceutical single import 15.3 billion, ring than decline 22.4%; exports decreased 31 billion 9.4%. Xu Ming analysis that benefit from last year's health reform implementation plan, as well as national 4 trillion yuan, pharmaceutical imports soared, therefore it stands also for this year's decline.
"Truly worthy of note is that this year the pharmaceutical export conditions extremely difficult. "Xu Ming stressed. It is learnt that from June of this year, the appreciation of the Renminbi against the US dollar exchange rate close to 3%, corporate profits were basically approximation can withstand the critical point. "If the financial crisis, the pharmaceutical export enterprises received no orders, that now is not afraid to pick up. "In addition, the EU market is affected by the debt crisis effects, such as the pharmaceutical market overall rendering stagnation, which restricted the export of Chinese medicine.
"Compared to the first half of this year, now the big list of enterprises receipt clearly reduced, but also continue to decline. "A pharmaceutical firms charge told reporters that now has to face both enterprises. "Because of domestic agricultural products and the prices of resource products continued to increase, further compression and export the pharmaceutical enterprises of profit. "
No comments:
Post a Comment